Publicaciones en las que colabora con MIGUEL ANGEL GONZÁLEZ TORRES (33)

2024

  1. Corrigendum to “Prolactin and morning cortisol concentrations in antipsychotic naïve first episode psychosis: A systematic review and meta-analysis” [Psychoneuroendocrinology 150 (2023) 106049] (Psychoneuroendocrinology (2023) 150, (S0306453023000276), (10.1016/j.psyneuen.2023.106049))

    Psychoneuroendocrinology

2023

  1. Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment

    Pharmaceutics, Vol. 15, Núm. 8

  2. Prolactin and morning cortisol concentrations in antipsychotic naïve first episode psychosis: A systematic review and meta-analysis

    Psychoneuroendocrinology, Vol. 150

  3. Psychosis and substance abuse increase the COVID-19 mortality risk

    Psychological Medicine, Vol. 53, Núm. 9, pp. 4236-4244

  4. The transition to Schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use

    Psychiatry Research, Vol. 328

2022

  1. Attachment anxiety as mediator of the relationship between childhood trauma and personality dysfunction in borderline personality disorder

    Clinical Psychology and Psychotherapy, Vol. 29, Núm. 2, pp. 501-511

  2. Diagnostic stability in substance-induced psychosis

    Revista de Psiquiatria y Salud Mental, Vol. 15, Núm. 4, pp. 272-280

2021

  1. Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Sex seems to matter

    Schizophrenia Research, Vol. 228, pp. 382-384

  2. Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis

    European Psychiatry, Vol. 64, Núm. 1

2020

  1. Genetic modulation of facial emotion recognition in borderline personality disorder

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 99

2019

  1. GAD1 gene polymorphisms are associated with bipolar I disorder and with blood homovanillic acid levels but not with plasma GABA levels

    Neurochemistry International, Vol. 124, pp. 152-161

2016

  1. COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients

    Pharmacogenomics, Vol. 17, Núm. 8, pp. 837-851

2015

  1. Undertreatment of human immunodeficiency virus in psychiatric inpatients: A cross-sectional study of seroprevalence and associated factors

    Neuropsychiatric Disease and Treatment, Vol. 11, pp. 1421-1426

2014

  1. Adopción y alteraciones de conducta en la adolescencia. Estudio en población hospitalaria

    Anales de Pediatria, Vol. 80, Núm. 1, pp. 21-27

  2. Adopción y alteraciones de conducta en la adolescencia: Estudio en población hospitalaria

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 80, Núm. 1, pp. 21-27

  3. Relación entre el consumo de cannabis y otras drogas y patología psiquiátrica en adolescentes: propuestas de atención en salud mental intra y extrahospitalaria de Osakidetza en Euskadi : proyecto de investigación comisionada

    Servicio Central de Publicaciones = Argitalpen Zerbitzu Nagusia

2013

  1. The Influence of the Val158Met Catechol-O-Methyltransferase Polymorphism on the Personality Traits of Bipolar Patients

    PLoS ONE, Vol. 8, Núm. 4

2012

  1. Quality of life and motivation to change in eating disorders. Perception patient-psychiatrist

    Eating Behaviors, Vol. 13, Núm. 2, pp. 131-134

2011

  1. Catatonia: a propósito de un caso

    Revista de la Asociación Española de Neuropsiquiatría, Vol. 31, Núm. 109, pp. 111-119

  2. Variability of plasma homovanillic acid over 13 months in patients with Schizophrenia; Relationship with the clinical response and the wisconsin card sort test

    Neurochemical Research, Vol. 36, Núm. 8, pp. 1336-1343